Quantcast

Latest pharmaceutical industry Stories

2014-09-26 23:02:51

Transparency Market Research, in its latest report, estimates that the global computational biology market will report a CAGR of 21.3% from 2012 to 2018. Albany,NY (PRWEB) September 26, 2014 In its latest market research report published recently, Transparency Market Research, a U.S.-based market intelligence firm states that the global computational biology market is estimated to be worth US$2937.3 million by 2018. The report, titled “Computational Biology (Pharmacodynamics, Cellular...

2014-09-26 12:25:01

RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S. Food and Drug Administration (FDA) for conducting today's public meeting to better understand the daily experiences of those living with idiopathic pulmonary fibrosis (IPF), a serious and life-threatening lung disease in which most patients live only three to five years after diagnosis. The patient and caregiver stories that will be shared with the FDA and the public today may help shed light on...

2014-09-26 08:26:22

Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region ABBOTT PARK, Ill., Sept. 26, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets. Through purchase of the controlling interest and tender offers...

2014-09-26 08:25:31

SAN FRANCISCO, Sept. 26, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. MOVENTIG is an investigational, peripherally-acting...

2014-09-25 23:06:03

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced two appointments to the management structure of its Development and Clinical Services division, to further support its global customer needs. The move sees the creation of two new senior leadership roles to support drug development and clinical trial growth in the United States, Europe and Asia. Somerset, N.J....

2014-09-25 16:26:46

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr. Actavis' ANDA product is a generic version of Purdue Pharma's Butrans(®), which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for...

2014-09-25 16:26:37

SUNNYVALE, Calif. and SURESNES, France, Sept. 25, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) and Servier today announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat, thereby returning global development and commercialization rights to Pharmacyclics. "We thank Servier for their contribution in forwarding abexinostat to its current stage of...

2014-09-25 16:26:10

PHILADELPHIA, Sept. 25, 2014 /PRNewswire/ -- Global Track & Trace (GTT) was created in 2009 to support the Pharmaceutical Industry as it relates to the product serialization mandates. As part of this effort, GTT monitors global regulatory mandates, reports those updates to our members to support their business requirements. Excellis Health Solutions plays a lead role in developing the industry consortium platform, GTT, to bring the Pharmaceutical and Life Science industries...

2014-09-25 12:30:11

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 For six editions, this authoritative resource has defined the market opportunity for companies assisting in the beginning phase of the drug development process. 'Outsourcing in Drug Discovery' provides an in depth look into the...

2014-09-25 12:29:50

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'